var data={"title":"Typhoid vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Typhoid vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7126?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=typhoid-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Typhoid vaccine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=typhoid-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Typhoid vaccine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232369\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Typhim Vi;</li>\n      <li>Vivotif</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5275259\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Typherix;</li>\n      <li>Typhim Vi;</li>\n      <li>Vivotif</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232378\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial);</li>\n      <li>\n        Vaccine, Live (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232371\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Typhoid fever prevention: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary immunization:</i> One capsule on alternate days (day 1, 3, 5, and 7) for a total of 4 doses; all doses should be complete at least 1 week prior to potential exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Reimmunization (with repeated or continued exposure to typhoid fever):</i> Repeat full course of primary immunization every 5 years. Alternatively, in Canada, it is recommended to repeat a full course of primary immunization every 7 years (Canadian immunization guide).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> 0.5 mL given at least 2 weeks prior to expected exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Reimmunization (with repeated or continued exposure to typhoid fever):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Typhim Vi: 0.5 mL every 2 years (US labeling) or every 3 years (Canadian labeling)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Typherix [Canadian product]: 0.5 mL every 3 years</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232374\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=typhoid-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Typhoid vaccine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Typhoid fever prevention: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;6 years (US labeling) or &ge;5 years (Canadian labeling) and Adolescents: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;2 years and Adolescents: IM: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232372\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22815640\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22815641\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232355\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, enteric coated, Oral [live]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vivotif: Viable <i>S. typhi</i> Ty21a 2-10 x 10<sup>9</sup> colony-forming units [contains lactose 180-200 mg/capsule and sucrose 3.3-34.2 mg/capsule]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [inactivated]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Typhim Vi: Purified Vi capsular polysaccharide 25 mcg/0.5 mL (0.5 mL, 10 mL) [derived from <i>S. typhi</i> Ty2 strain]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232342\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951008\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Typherix: Vi capsular polysaccharide 25 mcg/0.5 mL (0.5 mL)  [derived from <i>S. typhi</i> Ty2 strain]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734165\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the CDC-approved Vaccine Information Statement (VIS) is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/typhoid.html&amp;token=LHu7kbGkhb1BRIgBifqmSqKWE4U5+3rWcSxWeY8RpP04bRpqrJwaPKECeqZvtpTvLMxUdTOOZbF4PofOpfXIuhA0i8kGRlde5pxOHvYVv1s=&amp;TOPIC_ID=10030\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/typhoid.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232358\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: For IM administration. Administer as a single 0.5 mL (25 mcg) injection into the deltoid muscle; younger children may also receive the dose in the anterolateral thigh. Not for gluteal administration. Do not administer Typhim Vi or Typherix [Canadian product] intravascularly. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). <b>Note:</b> For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]). US federal law requires that the name of medication, date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Swallow capsule whole soon after placing into mouth; do not chew or open capsule. Capsule should be taken with a cold or lukewarm beverage (&le;37&#730;C/98.6&#730;F). Take 1 hour prior to a meal. Avoid alcohol 1 hour before or 2 hours after administration; alcohol may disrupt the enteric coating.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232356\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Typhoid fever prevention:</b> Active immunization against typhoid fever caused by <i>Salmonella typhi</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immunization of adults and children &gt;6 years of age; complete the vaccine regimen at least 1 week before potential exposure to typhoid bacteria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Parenteral: Immunization of adults and children &ge;2 years of age; complete the vaccine regimen at least 2 weeks before potential exposure to typhoid bacteria.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Not for routine vaccination. In the United States (CDC/ACIP [Jackson 2015]) and Canada, use should be limited to:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Travelers to areas with a recognized risk of exposure to <i>S. typhi</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Persons with intimate exposure to a household contact with <i>S. typhi</i> fever or a known carrier</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Laboratory technicians with frequent exposure to <i>S. typhi</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional recommendations: May consider administration to travelers with achlorhydria, or receiving acid suppression therapy; anatomic or functional asplenia (Canadian Immunization Guide)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232349\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>In the US, all serious adverse reactions must be reported to the Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=10030\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b> In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Injection (incidence may vary based on age and/or product used):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Central nervous system: Malaise (4% to 24%), headache (16% to 20%), generalized ache (1% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Local: Tenderness at injection site (97% to 98%), pain at injection site (27% to 41%), induration at injection site (5% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle tenderness (&le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Miscellaneous: Fever (undefined 2% to 32%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dermatologic: Pruritus (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Gastrointestinal: Nausea (&le;8%), vomiting (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Local: Injection site: Erythema at injection site (&le;5%), swelling at injection site (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Miscellaneous: Fever greater than 100 to 101 degrees (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Postmarketing and/or case reports: Abdominal pain, anaphylaxis, angioedema, arthralgia, asthma, diarrhea, dizziness, flu-like symptoms, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, hypotension, inflammation at injection site (including angioedema and urticaria), intestinal perforation (jejunum), loss of consciousness, lymphadenopathy, malaise, neck pain, serum sickness, skin rash, syncope (with and without convulsions), tremor, urticaria, vasodilation, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Oral: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Central nervous system: Headache (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dermatologic: Skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Gastrointestinal: Abdominal pain (6%), nausea (6%), diarrhea (3%), vomiting (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Miscellaneous: Fever (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Postmarketing and/or case reports: Anaphylaxis, demyelinating disease, myalgia, pain, rheumatoid arthritis, sepsis, urticaria, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232361\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to any component of the vaccine. In addition, the oral vaccine is contraindicated with congenital or acquired immunodeficient state, acute febrile illness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Canadian immunization guidelines also contraindicate oral typhoid vaccine in pregnancy, acute gastrointestinal condition or inflammatory bowel disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232346\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Injection: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Injection: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: Injection: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]). Do not administer oral formulation during acute GI illness; vaccination may be deferred with persistent diarrhea or vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Injection: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Typhoid fever: Should not be used to treat typhoid fever or a chronic typhoid carrier. Not all recipients of typhoid vaccine will be fully protected against typhoid fever. Travelers should take all necessary precautions to avoid contact or ingestion of potentially contaminated food or water sources.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring inactive vaccine during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination or may have an adverse event secondary to replication. Live vaccine should generally not be administered. Household and close contacts of persons with altered immunocompetence may receive most age appropriate vaccines (ACIP [Kroger 2017]; IDSA [Rubin 2014]). Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained. Live vaccines should be administered &ge;4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; ve vaccines should not be administered for at least 3 months after immunosuppressive therapy (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Administer at least 2 weeks prior to expected exposure. According to the ACIP, the parenteral inactivated vaccine is equally as effective as the oral live vaccine; however, the parenteral vaccine may cause more adverse reactions (CDC/ACIP [Jackson 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral: Full immunization schedule should be completed at least 1 week prior to expected exposure. The complete immunization schedule must be followed to achieve optimum immune response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300191\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232350\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10030&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antibiotics: May diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<b> Exceptions: </b>Acetic Acid (Otic); Acetic Acid (Topical); Aluminum Acetate; Azithromycin (Ophthalmic); Aztreonam (Oral Inhalation); Bacitracin (Ophthalmic); Bacitracin (Systemic); Bacitracin (Topical); Benzoin; Capreomycin; Chlortetracycline; Ciprofloxacin (Ophthalmic); Clindamycin (Topical); Dapsone (Topical); Dibrompropamidine (Ophthalmic); Dibrompropamidine (Topical); Erythromycin (Ophthalmic); Erythromycin (Topical); Fidaxomicin; Framycetin; Fusidic Acid (Ophthalmic); Fusidic Acid (Topical); Gatifloxacin; Gentamicin (Ophthalmic); Gentamicin (Topical); Gentian Violet; Hexachlorophene; Mafenide; MetroNIDAZOLE (Topical); Mupirocin; Neomycin; Nitrofurazone; Oxychlorosene; Ozenoxacin; Polymyxin B; Povidone-Iodine (Topical); RifAXIMin; Silver Nitrate; Silver Sulfadiazine; Sulfacetamide (Ophthalmic); Sulfacetamide (Topical); Taurolidine; Tobramycin (Ophthalmic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Axicabtagene Ciloleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for at least 6 weeks prior to initiation of lymphodepleting therapy, during axicabtagene ciloleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclizumab: May enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Canadian labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment.  U.S. labeling does not mention this.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinal infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<b> Exceptions: </b>AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone (Systemic); Budesonide (Systemic); Corticotropin; Cortisone; Cytarabine (Liposomal); Deflazacort; Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live). Management: The ACIP guidelines state that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy. However, the ACR does not recommend avoiding live vaccines in patients being treated with leflunomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose 6-mercaptopurine (1.5 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of mercaptopurine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the adverse/toxic effect of Vaccines (Live). Ocrelizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proguanil: May diminish the therapeutic effect of Typhoid Vaccine. This applies only to the oral (live) typhoid vaccine. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with proguanil. When possible, proguanil should not be started within 10 days of the last vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Tisagenlecleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for two weeks prior to initiation of lymphodepleting therapy, during tisagenlecleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<b> Exceptions: </b>Adenovirus (Types 4, 7) Vaccine; Cholera Vaccine; Rotavirus Vaccine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232352\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4039581\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. The manufacturer of the Typhim Vi injection suggests delaying vaccination until the second or third trimester if possible. Untreated typhoid fever may lead to miscarriage or vertical intrauterine transmission causing neonatal typhoid (rare).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17969752\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if typhoid vaccine is excreted in breast milk. Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10166648\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">After injection, monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232345\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Virulent strains of <i>Salmonella typhi</i> cause disease by penetrating the intestinal mucosa and entering the systemic circulation via the lymphatic vasculature. One possible mechanism of conferring immunity may be the provocation of a local immune response in the intestinal tract induced by oral ingesting of a live strain with subsequent aborted infection. The ability of <i>S. typhi</i> to produce clinical disease (and to elicit an immune response) is dependent on the bacteria having a complete lipopolysaccharide. The live attenuate Ty21a strain lacks the enzyme UDP-4-galactose epimerase so that lipopolysaccharide is only synthesized under conditions that induce bacterial autolysis. Thus, the strain remains avirulent despite the production of sufficient lipopolysaccharide to evoke a protective immune response. Despite low levels of lipopolysaccharide synthesis, cells lyse before gaining a virulent phenotype due to the intracellular accumulation of metabolic intermediates.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Efficacy:</b> Based on a systematic review and meta-analysis, the estimated 2.5 to 3 year cumulative efficacy was 55% (95% confidence interval [CI]: 30% to 70%) for the injectable vaccine and 48% (CI: 34% to 58%) for the oral vaccine (CDC/ACIP [Jackson 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232360\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immunity to <i>Salmonella typhi</i>: Oral: ~1 week after completing the series; Parenteral: Antibody response develops within 2 weeks after a single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immunity: Oral: &gt;5 years; Parenteral: Typhim Vi: ~2 years, Typherix [Canadian product]: ~3 years</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422285\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Typhim VI Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/0.5 mL (0.5 mL): $114.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539952\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Tifim Vi (UA);</li>\n      <li>Typbar (TH);</li>\n      <li>Typh-Vax (NZ);</li>\n      <li>Typherix (HK, PH, VN);</li>\n      <li>Typhim Vi (AE, CN, CZ, HR, IE, IL, IS, LT, LU, LV, MT, PL, RO, SA, SI, SK, VN);</li>\n      <li>Typhim VI (AU, BG, CO, CR, DO, EE, FI, GT, HK, ID, KR, MY, NZ, PE, PH, PK, SG, SV, TH, TW);</li>\n      <li>Typhoral (IN);</li>\n      <li>Typhovax (KR);</li>\n      <li>Tyrix Vi (KR);</li>\n      <li>Vivotif (DE, GB);</li>\n      <li>Vivotif Berna (AE, AT, CH, DK, EG, HK, IT, KR, KW, MY, NL, PH, QA, SA);</li>\n      <li>Vivotif Berna Capsule (NO);</li>\n      <li>Vivotif Oral (AU);</li>\n      <li>Vivotif Oralt Vaccin (SE);</li>\n      <li>Zerotyph (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Begier EM, Burewn DR, Haber P, et al, &ldquo;Postmarketing Safety Surveillance for Typhoid Fever Vaccines From the Vaccine Adverse Event Reporting System, July 1990 Through June 2002,&rdquo; <i>Clin Infect Dis</i>, 2004, 38(6):771-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/typhoid-vaccine-drug-information/abstract-text/14999618/pubmed\" target=\"_blank\" id=\"14999618\">14999618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Immunization Guide, Public Health Agency of Canada. http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-typh-eng.php; accessed November 17, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferreccio C, Levine MM, Rodriguez, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: A field trial in an endemic area. <i>J Infect Dis</i>. 1989;159(4):766-769.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/typhoid-vaccine-drug-information/abstract-text/2647863 /pubmed\" target=\"_blank\" id=\"2647863 \">2647863 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guzman CA, Borsutzky S, Griot-Wenk M, et al, &ldquo;Vaccines Against Typhoid Fever,&rdquo; <i>Vaccine</i>, 2006, 24(18):3804-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/typhoid-vaccine-drug-information/abstract-text/16278037/pubmed\" target=\"_blank\" id=\"16278037\">16278037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine &ndash; advisory committee on immunization practices, United States, 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(11):305-308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/typhoid-vaccine-drug-information/abstract-text/25811680/pubmed\" target=\"_blank\" id=\"25811680\">25811680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parry CM, Hien TT, Dougan G, et al, &ldquo;Typhoid Fever,&rdquo; <i>N Engl J Med</i>, 2002, 347(22):1770-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/typhoid-vaccine-drug-information/abstract-text/12456854/pubmed\" target=\"_blank\" id=\"12456854\">12456854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/typhoid-vaccine-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/typhoid-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Typherix (typhoid vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Typhim Vi (typhoid vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vivotif (typhoid vaccine) [prescribing information]. Redwood City, CA: PaxVax Inc.; September 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10030 Version 131.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F232369\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5275259\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F232378\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F232371\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F232374\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F232372\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22815640\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22815641\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232355\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F232342\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5951008\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734165\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F232358\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F232356\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F232349\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232361\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232346\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300191\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F232350\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F232352\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4039581\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17969752\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10166648\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232345\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F232360\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422285\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539952\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10030|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=typhoid-vaccine-patient-drug-information\" class=\"drug drug_patient\">Typhoid vaccine: Patient drug information</a></li><li><a href=\"topic.htm?path=typhoid-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Typhoid vaccine: Pediatric drug information</a></li></ul></div></div>","javascript":null}